Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States

H. W. Choi, K. Miele, David Wesley Dowdy, Maunank Shah

Research output: Contribution to journalArticle

Abstract

SETTING: Conventional approaches to tuberculosis (TB) diagnosis and resistance testing are slow. The Xpert®MTB/RIF assay is an emerging molecular diagnostic assay for rapid TB diagnosis, offering results within 2 hours. However, the cost-effectiveness of implementing Xpert in settings with low TB prevalence, such as the United States, is unknown. OBJECTIVE: We evaluated the cost-effectiveness of incorporating Xpert into TB diagnostic algorithms in the United States compared to existing diagnostics. DESIGN: A decision-analysis model compared current TB diagnostic algorithms in the United States to algorithms incorporating Xpert. Primary outcomes were the costs and quality-adjusted life years (QALYs) accrued with each strategy; cost-effectiveness was represented using incremental cost-effectiveness ratios (ICER). RESULTS: Xpert testing of a single sputum sample from TB suspects is expected to result in lower total health care costs per patient (US$2673) compared to diagnostic algorithms using only sputum microscopy and culture (US$2728) and improved health outcomes (6.32 QALYs gained per 1000 TB suspects). Compared to existing molecular assays, implementation of Xpert in the United States would be considered highly cost-effective (ICER US$39 992 per QALY gained). CONCLUSION: TB diagnostic algorithms incorporating Xpert in the United States are highly cost-effective.

Original languageEnglish (US)
Pages (from-to)1328-1335
Number of pages8
JournalInternational Journal of Tuberculosis and Lung Disease
Volume17
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Pulmonary Tuberculosis
Cost-Benefit Analysis
Tuberculosis
Quality-Adjusted Life Years
Sputum
Costs and Cost Analysis
Decision Support Techniques
Molecular Pathology
Health Care Costs
Microscopy
Health

Keywords

  • Diagnostics
  • Genexpert
  • MTD

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. / Choi, H. W.; Miele, K.; Dowdy, David Wesley; Shah, Maunank.

In: International Journal of Tuberculosis and Lung Disease, Vol. 17, No. 10, 01.10.2013, p. 1328-1335.

Research output: Contribution to journalArticle

@article{78bab2bf3e8b45cabefadf1eb9776f70,
title = "Cost-effectiveness of Xpert{\circledR} MTB/RIF for diagnosing pulmonary tuberculosis in the United States",
abstract = "SETTING: Conventional approaches to tuberculosis (TB) diagnosis and resistance testing are slow. The Xpert{\circledR}MTB/RIF assay is an emerging molecular diagnostic assay for rapid TB diagnosis, offering results within 2 hours. However, the cost-effectiveness of implementing Xpert in settings with low TB prevalence, such as the United States, is unknown. OBJECTIVE: We evaluated the cost-effectiveness of incorporating Xpert into TB diagnostic algorithms in the United States compared to existing diagnostics. DESIGN: A decision-analysis model compared current TB diagnostic algorithms in the United States to algorithms incorporating Xpert. Primary outcomes were the costs and quality-adjusted life years (QALYs) accrued with each strategy; cost-effectiveness was represented using incremental cost-effectiveness ratios (ICER). RESULTS: Xpert testing of a single sputum sample from TB suspects is expected to result in lower total health care costs per patient (US$2673) compared to diagnostic algorithms using only sputum microscopy and culture (US$2728) and improved health outcomes (6.32 QALYs gained per 1000 TB suspects). Compared to existing molecular assays, implementation of Xpert in the United States would be considered highly cost-effective (ICER US$39 992 per QALY gained). CONCLUSION: TB diagnostic algorithms incorporating Xpert in the United States are highly cost-effective.",
keywords = "Diagnostics, Genexpert, MTD",
author = "Choi, {H. W.} and K. Miele and Dowdy, {David Wesley} and Maunank Shah",
year = "2013",
month = "10",
day = "1",
doi = "10.5588/ijtld.13.0095",
language = "English (US)",
volume = "17",
pages = "1328--1335",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "10",

}

TY - JOUR

T1 - Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States

AU - Choi, H. W.

AU - Miele, K.

AU - Dowdy, David Wesley

AU - Shah, Maunank

PY - 2013/10/1

Y1 - 2013/10/1

N2 - SETTING: Conventional approaches to tuberculosis (TB) diagnosis and resistance testing are slow. The Xpert®MTB/RIF assay is an emerging molecular diagnostic assay for rapid TB diagnosis, offering results within 2 hours. However, the cost-effectiveness of implementing Xpert in settings with low TB prevalence, such as the United States, is unknown. OBJECTIVE: We evaluated the cost-effectiveness of incorporating Xpert into TB diagnostic algorithms in the United States compared to existing diagnostics. DESIGN: A decision-analysis model compared current TB diagnostic algorithms in the United States to algorithms incorporating Xpert. Primary outcomes were the costs and quality-adjusted life years (QALYs) accrued with each strategy; cost-effectiveness was represented using incremental cost-effectiveness ratios (ICER). RESULTS: Xpert testing of a single sputum sample from TB suspects is expected to result in lower total health care costs per patient (US$2673) compared to diagnostic algorithms using only sputum microscopy and culture (US$2728) and improved health outcomes (6.32 QALYs gained per 1000 TB suspects). Compared to existing molecular assays, implementation of Xpert in the United States would be considered highly cost-effective (ICER US$39 992 per QALY gained). CONCLUSION: TB diagnostic algorithms incorporating Xpert in the United States are highly cost-effective.

AB - SETTING: Conventional approaches to tuberculosis (TB) diagnosis and resistance testing are slow. The Xpert®MTB/RIF assay is an emerging molecular diagnostic assay for rapid TB diagnosis, offering results within 2 hours. However, the cost-effectiveness of implementing Xpert in settings with low TB prevalence, such as the United States, is unknown. OBJECTIVE: We evaluated the cost-effectiveness of incorporating Xpert into TB diagnostic algorithms in the United States compared to existing diagnostics. DESIGN: A decision-analysis model compared current TB diagnostic algorithms in the United States to algorithms incorporating Xpert. Primary outcomes were the costs and quality-adjusted life years (QALYs) accrued with each strategy; cost-effectiveness was represented using incremental cost-effectiveness ratios (ICER). RESULTS: Xpert testing of a single sputum sample from TB suspects is expected to result in lower total health care costs per patient (US$2673) compared to diagnostic algorithms using only sputum microscopy and culture (US$2728) and improved health outcomes (6.32 QALYs gained per 1000 TB suspects). Compared to existing molecular assays, implementation of Xpert in the United States would be considered highly cost-effective (ICER US$39 992 per QALY gained). CONCLUSION: TB diagnostic algorithms incorporating Xpert in the United States are highly cost-effective.

KW - Diagnostics

KW - Genexpert

KW - MTD

UR - http://www.scopus.com/inward/record.url?scp=84884639475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884639475&partnerID=8YFLogxK

U2 - 10.5588/ijtld.13.0095

DO - 10.5588/ijtld.13.0095

M3 - Article

C2 - 24025386

AN - SCOPUS:84884639475

VL - 17

SP - 1328

EP - 1335

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 10

ER -